Developing smart liposomes that release drugs in response to reactive oxygen species
Liposome Targeting and Triggered Release Driven by Reactive Oxygen Species
This study is testing a new way to deliver medicine directly to sick cells by using special tiny bubbles that only release the drugs when they find harmful substances in those cells, which could help patients get more effective treatments with fewer side effects.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tennessee Knoxville NIH-funded |
| Lab location | 1 site (Knoxville, United States) |
| Project ID | NIH-10439073 on NIH RePORTER |
What this research studies
This research focuses on creating advanced liposomes that can deliver drugs specifically to diseased cells by responding to high levels of reactive oxygen species (ROS). The approach involves designing liposomes that can release their therapeutic cargo only when they encounter these ROS, which are often present in diseased tissues. By using synthetic lipid switches, the researchers aim to enhance the effectiveness of drug delivery while minimizing side effects. Patients may benefit from more targeted treatments that improve drug potency and reduce off-target impacts.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with conditions that involve high levels of reactive oxygen species, such as certain cancers or inflammatory diseases.
Not a fit: Patients with conditions that do not involve reactive oxygen species or those who are not candidates for liposomal drug delivery may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer drug delivery systems for patients with diseases characterized by elevated reactive oxygen species.
How similar studies have performed: Other research has shown promise in using targeted liposomal delivery systems, indicating that this approach has potential for success.
Where this research is happening
Knoxville, United States
- University of Tennessee Knoxville — Knoxville, United States (Active)
Researchers
- Principal investigator: Best, Michael D. — University of Tennessee Knoxville
- Study coordinator: Best, Michael D.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.